Kodiak Sciences rises after eye-disease drugs meet late-stage trial goals

By Reuters News

** Shares of drug developer Kodiak Sciences KOD.O jump 141.1% to $78, hitting highest level in more than four years

** Stock set for biggest daily percentage rise ever, if gains hold

** Co says its experimental drugs Zenkuda and tabirafusp-ted met the main goals of a late-stage trial in patients with wet age-related macular degeneration

** Both drugs achieved vision gains at one year that were not inferior to aflibercept, the comparison treatment

** Wet age-related macular degeneration causes abnormal blood vessels to leak beneath the retina and can lead to loss of central vision

** About 54% of Zenkuda patients reached a six-month dosing interval, potentially reducing the number of eye injections needed

** Both drugs showed safety broadly consistent with aflibercept; Kodiak plans further analyses to identify which patients may benefit most from tabirafusp-ted

** Co plans to seek US approval for Zenkuda in Q4 2026, using results from five successful late-stage studies across three retinal diseases

** Including session's move, KOD up 174.4% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.